Huntington’s Disease
Watch Time: 7 mins

Rajeev Kumar, MDS 2022: ANX005, a humanized monoclonal antibody for Huntington’s disease, the phase 2 study results

Published Online: October 14th 2022

The phase 2 study results of ANX005, a humanized monoclonal antibody targeting C1q, for patients with Huntington’s disease were presented at MDS 2022. In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the key results, their significance and the next steps.

The abstract entitled ‘Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)’ was presented at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain, 15 – 18 September 2022.

Questions:

  1. Your study primarily examined safety and tolerability signals for ANX005 – what were your key findings? (0:24)
  2. What did you observe in the PK/PD and biomarker data, which examined drug availability in the blood and cerebrospinal fluid? (1:46)
  3. What effect did ANX005 have on measures of efficacy in improving the course of Huntington’s disease? (3:16)
  4. What is the significance of these phase 2 findings, and what are the next steps in evaluating the potential role of ANX005 in disease modification for people with Huntington’s disease? (5:12)

Disclosures: Rajeev Kumar is a consultant for Abbvie, Acorda Therapeutics, Annexon, Cerevel Therapeutics, Genentech, Roche, Supernus Pharmaceuticals and Teva Pharmaceuticals. He is on the speaker’s bureau for Acorda Therapeutics, Kyowa Kirin, Supernus Pharmaceuticals and Teva Pharmaceuticals and has stock ownership in the following companies: CenExel Clinical Research Holdings,  LLC and Research Catalyst. Rajeev Kumar has received research grant support from Abbvie, Addex Pharma, Biohaven, Annexon Biosciences, Biovie, Cerevel Therapeutics, CHDI Foundation, CND Life Sciences, Enterin, Impax Laboratories, Integrative Research Laboratories, Lundbeck, Neuraly, Neurocrine Biosciences, Neuroderm, Neuron23, Pharma Two B, Prilenia Therapeutics, PTC Therapeutics, Revance Therapeutics, Roche, Sage Therapeutics, Sanofi, Supernus Pharmaceuticals, Takeda, Transposon Therapeutics and Triplet Therapeutics.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of MDS 2022

Access more content on Huntington’s Disease here

Share this Video
Related Videos In Huntington’s Disease
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72